e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Drug target expression in pulmonary langerhans´cell histiocytosis
J. Loeffler-Ragg, E. Stacher, J. Guenther, P. Stoitzner, K. Cima, S. Desole, H. H. Popper, C. M. Kaehler (Austria)
Source:
Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Session:
Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Session type:
Thematic Poster Session
Number:
2345
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Loeffler-Ragg, E. Stacher, J. Guenther, P. Stoitzner, K. Cima, S. Desole, H. H. Popper, C. M. Kaehler (Austria). Drug target expression in pulmonary langerhans´cell histiocytosis. Eur Respir J 2010; 36: Suppl. 54, 2345
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Expression of potential therapeutic targets in pulmonary Langerhans´ cell histiocytosis
Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Year: 2009
Pulmonary Langerhans‘ cell histiocytosis (PLCH). Report of two cases diagnosed with pulmonary vascular involvement via exercise tests
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
A case with pulmonary histiocytosis X and lung cancer
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
Pulmonary Langerhans' cell histiocytosis
Source: Respipedia Article
Year: 2016
Chemotherapy in patients with pulmonary Langerhans cell histiocytosis
Source: International Congress 2018 – Progress in rare interstitial lung diseases
Year: 2018
Cladribine improves lung cysts and pulmonary function in a child with histiocytosis
Source: Eur Respir J 2015; 45: 831-833
Year: 2015
Clinical study of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012
Paediatric pulmonary Langerhans cell histiocytosis
Source: Breathe, 16 (2) 200003; 10.1183/20734735.0003-2020
Year: 2020
Pulmonary histiocytosis triggered by marijuana- and nicotine-abuse
Source: Eur Respir J 2002; 20: Suppl. 38, 338s
Year: 2002
Pulmonary hypertension in pulmonary Langerhans’ cell histiocytosis
Source: Eur Respir Mon 2012; 57: 161-165
Year: 2012
Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis
Source: ERJ Open Res, 4 (1) 00089-2017; 10.1183/23120541.00089-2017
Year: 2018
Pulmonary Langerhans cell histiocytosis
Source: Annual Congress 2008 - PG5 - Interstitial lung diseases: selected orphan diseases
Year: 2008
Pulmonary Langerhans‘ cell histiocytosis
Source: Eur Respir J 2006; 28: Suppl. 50, 826s
Year: 2006
Pulmonary Langerhans‘ cell histiocytosis (PLCH): A new UK register
Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis
Year: 2012
Adult pulmonary Langerhans‘ cell histiocytosis and lung cancer
Source: Annual Congress 2009 - Clinical aspects and epidemiology in lung cancer
Year: 2009
Pulmonary Langerhans' cell histiocytosis
Source: Eur Respir Mon; 2009: 46: 155–175
Year: 2009
Pathological findings in histiocytosis X with pulmonary hypertension
Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV
Year: 2012
Genetic landscape of pulmonary langerhans cell histiocytosis
Source: International Congress 2018 – Progress in rare interstitial lung diseases
Year: 2018
Special features in progress of cases with pulmonary histiocytosis X
Source: Eur Respir J 2002; 20: Suppl. 38, 59s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept